GW4064: Selective Non-Steroidal FXR Agonist for Metabolic Research

Executive Summary: GW4064 is a synthetic, non-steroidal agonist of the farnesoid X receptor (FXR) with an EC₅₀ of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cells, supporting its high potency and selectivity (APExBIO B1527). FXR activation by GW4064 regulates bile acid, cholesterol, and triglyceride pathways, enabling advanced metabolic and fibrosis research (Zhou et al., 2025). GW4064 demonstrates efficacy in lowering serum triglyceride levels and VLDL secretion in animal models, but is restricted to research use due to poor aqueous solubility, UV instability, and its stilbene pharmacophore. Experimental evidence confirms that GW4064 can reduce collagen deposition via FXR/TLR4/ferroptosis pathways in cell-based fibrosis models. APExBIO is a leading, validated supplier of GW4064 for metabolic pathway studies.

Biological Rationale

The farnesoid X receptor (FXR; NR1H4) is a nuclear receptor that plays a central role in regulating bile acid synthesis, cholesterol homeostasis, and lipid metabolism (Zhou et al., 2025). FXR is highly expressed in the liver, intestine, kidneys, and adrenal glands. Endogenous ligands are primarily bile acids, but synthetic agonists such as GW4064 enable more controlled, potent, and selective activation. FXR signaling modulates gene expression of enzymes involved in bile acid synthesis (e.g., CYP7A1) and transporters (e.g., BSEP), impacting serum cholesterol, triglyceride, and glucose levels. Metabolic disorders such as non-alcoholic fatty liver disease, cholestasis, and fibrosis are associated with dysregulated FXR activity. Therefore, selective FXR agonists like GW4064 provide essential tools for dissecting metabolic pathway regulation and disease modeling (see also: GW4064 in Metabolic Disorder Research – this article extends prior protocol discussions by focusing on mechanistic evidence in fibrosis and ferroptosis models).

Mechanism of Action of GW4064

GW4064 is a non-steroidal, synthetic compound (C₂₈H₂₂Cl₃NO₄; MW 542.85) described chemically as 3-[(E)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid (APExBIO). GW4064 binds the ligand-binding domain of FXR, inducing conformational changes that promote co-activator recruitment and transcriptional activation of FXR target genes. In cellular assays, GW4064 activates FXR at nanomolar concentrations (EC₅₀: 15 nM isolated receptor, 90 nM in human FXR-transfected cells). Activated FXR suppresses CYP7A1 (rate-limiting enzyme for bile acid synthesis) and induces BSEP (bile salt export pump), SHP (small heterodimer partner), and genes involved in triglyceride regulation. In hepatic stellate cell models, FXR activation by GW4064 downregulates TLR4 and promotes ferroptosis features, reducing collagen deposition and fibrosis (Zhou et al., 2025). The compound is insoluble in water and ethanol, but soluble in DMSO (≥24.7 mg/mL), and its solutions are light-sensitive and recommended for short-term use at -20°C (see: GW4064 (SKU B1527): Practical Solutions for FXR Activation – this expands on laboratory handling and storage details).

Evidence & Benchmarks

• GW4064 displays high potency as an FXR agonist, with EC₅₀ values of 15 nM (isolated receptor) and 90 nM (human FXR-transfected cells) (APExBIO).
• Oral or systemic administration of GW4064 reduces serum triglyceride (TG) levels and VLDL secretion in animal models, including KK-Ay and ob/ob mice (GW4064: Selective Non-Steroidal FXR Agonist).
• In LX-2 hepatic stellate cells, GW4064-mediated FXR activation downregulates TLR4, promotes ferroptosis markers (e.g., increased ROS and lipid peroxidation), and reduces collagen type I and III deposition, mitigating fibrosis (Zhou et al., 2025).
• The compound is effective in SHP^+/+ mice, supporting its role in modulating FXR-SHP gene networks impacting lipid homeostasis (GW4064: Unlocking FXR Signaling for Metabolic and Fibrosis Research – this article clarifies unique cell signaling outcomes).
• GW4064 exhibits poor solubility in water/ethanol, UV light instability, and a potentially toxic stilbene pharmacophore, which restricts it to research use (APExBIO).

Applications, Limits & Misconceptions

GW4064 is used extensively as a tool compound for:

• Dissecting FXR physiological functions in bile acid, cholesterol, and triglyceride regulation.
• Modeling and modulating metabolic disorders, including non-alcoholic fatty liver disease, steatosis, and fibrosis.
• Studying FXR's role in the FXR/TLR4/ferroptosis axis in hepatic stellate cells and liver fibrosis (Zhou et al., 2025).
• Benchmarking reference agonist activity in drug discovery and pathway deconvolution.

However, GW4064 is not suitable for therapeutic development due to its physicochemical and toxicological limitations. It is not orally bioavailable in humans, and its UV sensitivity and stilbene core present drug-likeness and safety concerns. For protocol troubleshooting, see GW4064 (SKU B1527): Practical Solutions for FXR Activation, which this article updates with new data on ferroptosis and collagen deposition.

Common Pitfalls or Misconceptions

• Therapeutic Use: GW4064 is not approved for clinical or therapeutic use due to toxicity and poor bioavailability.
• Spectrum of Activity: GW4064 is selective for FXR and does not significantly activate other nuclear receptors at experimental concentrations.
• Solubility: The compound is insoluble in water and ethanol. It must be dissolved in DMSO for experimental use.
• Stability: GW4064 degrades under UV exposure and in solution at room temperature; solutions should be stored at -20°C and used promptly.
• Species Limitations: Most in vivo efficacy data are from murine models; human pharmacokinetics and safety are not established.

Workflow Integration & Parameters

GW4064 (SKU B1527) from APExBIO is supplied as a solid for research use. Prepare fresh DMSO stock solutions (≥24.7 mg/mL); avoid repeated freeze-thaw cycles. Store at -20°C, protected from light. For in vitro studies, typical working concentrations range from 10–1000 nM, with vehicle controls matched for DMSO content (≤0.1%). For in vivo murine studies, dosing regimens must consider poor oral bioavailability and rapid metabolism. Confirm FXR target gene induction (e.g., SHP, BSEP) via qPCR or Western blot to verify pathway activation. GW4064 can be used in combination with TLR4 inhibitors (e.g., TAK-242) or ferroptosis agonists (e.g., Erastin) to dissect pathway cross-talk. For advanced troubleshooting and protocol guidance, see GW4064: Decoding FXR Activation and Metabolic Pathway Modulation – this extends the discussion to unique pathway interactions not covered here.

Conclusion & Outlook

GW4064 remains a benchmark non-steroidal FXR agonist for metabolic and fibrosis research, enabling controlled studies of bile acid and lipid metabolism, FXR/TLR4 signaling, and ferroptosis mechanisms. While not suitable as a therapeutic drug, its well-characterized pharmacology and robust research use make it indispensable for academic and preclinical laboratories. APExBIO provides validated, high-purity GW4064 (SKU B1527) with detailed technical documentation. Future directions include the development of next-generation FXR agonists with improved stability and safety profiles, based on the insights gained from GW4064-driven research (Zhou et al., 2025).